On Nov. 5, the Chinese Ministry of Commerce reported it would lift the export ban on Illumina Inc., which had been in place ...

Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced ...

San Francisco Bay Area researchers from UC Berkeley, UC San Francisco and Stanford University have combined their ...

The U.S. Patent and Trademark Office (PTO) has resurrected a previous policy that requires parties to a proceeding at the ...

Eli Lilly and Co.’s amylin receptor agonist, eloralintide, showed impressive weight loss and improved tolerability in phase II results reported at ObesityWeek 2025, setting the stage for a phase III ...

Billiontoone Inc. saw its shares surge well beyond the already upsized $60 IPO price, opening at $100 each, giving the ...

A collaborative effort is trying to construct the cell atlas of the developing brains of humans and animal models. Using advanced single-cell and spatial technologies, they mapped how brain cell types ...

Neok Bio Inc. was formed earlier this year and is already on schedule to file an IND in a few months for its two bispecific ...

Bavarian Nordic A/S will continue operating as an independent public company after an offer to be acquired by two private equity firms failed to win sufficient shareholder approval.

Industry watchers were surprised when Eli Lilly and Co.’s oral GLP-1 candidate, orforglipron, did not appear among the first nine recipients of the U.S. FDA’s commissioner’s national priority voucher ...

With strong phase II data in hand from its trial testing EVO-756 in chronic inducible urticaria (CIndU) – hives triggered by a specific cause – Evommune Inc. priced its IPO of about 9.3 million shares ...

Biopharma happenings, including deals and partnerships, and other news in brief: Ailux, Atai, Aveo, Beckley, BMS, Dispatch, Eli Lilly, Evotec, Hibercell, Karo, Moberg, Nona, Polyactiva, Raresight, ...